Phathom Pharmaceuticals, Inc. PHAT Interest Expense
Interest Expense at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Phathom Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:InterestExpenseNonoperating.
The official record: Phathom Pharmaceuticals, Inc.’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Phathom Pharmaceuticals, Inc.'s interest expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Phathom Pharmaceuticals, Inc.'s interest expense?
- Phathom Pharmaceuticals, Inc. (PHAT) reported interest expense of $15.8M in Q1 2026.
- How has Phathom Pharmaceuticals, Inc.'s interest expense changed year-over-year?
- Phathom Pharmaceuticals, Inc.'s interest expense decreased by 12.6% year-over-year, from $18.07M to $15.8M.
- What is the long-term trend for Phathom Pharmaceuticals, Inc.'s interest expense?
- Over 4 years (2021 to 2025), Phathom Pharmaceuticals, Inc.'s interest expense has grown at a 78.0% compound annual growth rate (CAGR), from $6.79M to $68.12M.
- What does interest expense mean?
- Cost of borrowing — interest paid or accrued on bonds, bank loans, credit facilities, finance leases, and other debt obligations.